A total of 64 research companies get to share SEK 65 million in Vinnova’s latest dividend of Forska och Väx funding. Among the companies are 15 life science firms.
Each of the 15 companies get grants between SEK 500 000 and SEK 3 500 000. Follicum and Hansa Medical are two of companies getting most funding, SEK 3.5 million and 3.4 million respectively. Follicum is developing a protein based treatment for hair loss and Hansa Medical is investing the money in a phase II study with the company’s drug candidate Ides.
The purpose with the Forska och Väx funding is to support small and medium sized innovative companies with the potential to grow.